Stock ARQT ARCUTIS BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
10.02 USD -3.93% Intraday chart for Arcutis Biotherapeutics, Inc. +7.74% +210.22%
Jul. 09 Arcutis Biotherapeutics Gets FDA Approval for Atopic Dermatitis Supplemental NDA DJ
Jul. 09 Arcutis Biotherapeutics' Zoryve Gets US FDA Approval for Atopic Dermatitis MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Arcutis Biotherapeutics Gets FDA Approval for Atopic Dermatitis Supplemental NDA
DJ
Arcutis Biotherapeutics' Zoryve Gets US FDA Approval for Atopic Dermatitis
MT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
GL
Arcutis Biotherapeutics, Inc. Announces the U.S. Food and Drug Administration's Approval of the Supplemental New Drug Application for ZORYVE (Roflumilast) Cream
CI
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
GL
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
AQ
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
CI
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Transcript : Arcutis Biotherapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
Sector Update: Health Care Stocks Mixed Premarket Tuesday
MT
Arcutis Biotherapeutics Says Experimental Cream Showed Improvements in Atopic Dermatitis Symptoms
MT
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
GL
Arcutis Biotherapeutics, Inc. Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (Ad) in Adults and Children Down to Age Six Presented At Revolutionizing Alopecia Areata, and Eczema Conference
CI
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
GL
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
AQ
Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
AQ
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARQT Stock
  4. News Arcutis Biotherapeutics, Inc.